Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Katherine Standley

Neurology Tampa, FL Doctor of Osteopathy

NPI 1154556181 CMS profile 98205

3000 Medical Park Dr Ste 510, Tampa, FL 33613

Open in the dashboard

General payments

$734,809

1,453 records reported · program years 2019–2025

Research payments

$30,861

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$387,837 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Katherine Standley of Tampa, FL is reported in the CMS Open Payments database as having received $734,809 across 1,453 general payments and $30,861 in research payments paid to them. Separately, studies naming them as principal investigator received $387,837 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,275 2
2022 General $97,013 218
2021 General $249,707 465
2020 General $132,938 293
2019 General $252,876 475
2019 Research $30,861 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Standley
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Katherine Standley were reported at $2,275. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Katherine Standley Neurology median Middle half National median
2019 $252,876 $474 $118–$2,177 $163
2020 $132,938 $367 $82–$2,309 $114
2021 $249,707 $438 $104–$2,547 $132
2022 $97,013 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $2,275 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $209,645 305 payments
  2. Biohaven Pharmaceuticals, Inc. $124,142 155 payments
  3. Genzyme Corporation $122,708 167 payments
  4. Genentech USA, Inc. $59,157 90 payments
  5. Biogen, Inc. $58,078 88 payments
  6. Teva Pharmaceuticals USA, Inc. $40,242 113 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $38,502 50 payments
  8. Lilly USA, LLC $37,368 92 payments
  9. AbbVie, Inc. $24,222 74 payments
  10. Allergan Inc. $10,257 57 payments
  11. Other $10,488 262 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $639,445 356 payments
  2. Consulting Fee $36,641 18 payments
  3. Travel and Lodging $36,101 195 payments
  4. Food and Beverage $22,568 882 payments
  5. Education $55 2 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $209,918 329 payments
  2. NURTEC ODT $162,644 205 payments
  3. OCREVUS $59,157 90 payments
  4. AUBAGIO Multiple Sclerosis $54,345 63 payments
  5. LEMTRADA $46,627 65 payments
  6. AJOVY $29,387 59 payments
  7. UBRELVY $23,968 45 payments
  8. VUMERITY $23,674 35 payments
  9. AUBAGIO Neurology $21,795 42 payments
  10. EMGALITY $19,357 37 payments
  11. Other $64,409 470 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $30,861 1 payment

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$6,696

Medicare's payments for the services billed

Medicare patients

45

Average age 77

Services billed

62

21 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 67%
Depression 56%
Diabetes 51%
Chronic kidney disease 51%
Heart failure 47%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,454 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record